COVID-19 Funding Opportunities

The MSI STEM Research & Development Consortium (MSRDC) – $9 Billion In Funding Through Non-Competed Awards (Rather Than Grants or Contracts), Submit Your Capabilities To Get Started

Icahn School of Medicine at Mount Sinai has recently become a partner institution of the Minority Serving Institution Research STEM Research & Development Consortium (MSRDC). This partnership offers significant advantages to Mount Sinai researchers and the consortium members through collaborative work which include funding opportunities that would otherwise be unavailable to Sinai researchers.  In addition, MSRDC recently posted a ‘Call to Action to Combat COVID-19’ for which the United States Government has prioritized $9 billion in funding in response to this new disease.  Some of the federal agencies include:

  • Centers for Disease Control and Prevention (CDC)
  • National Institutes of Health (NIH)
  • Food and Drug Administration (FDA)
  • Department of State (DOS) … and more.

Some Areas of Focus:

  • Detection and testing
  • Development of vaccines and therapeutics
  • Public health interventions
  • Medical device development and engineering …and more.

In order to be part of this collaboration, it is necessary that interested investigators submit their capabilities to the MSRDC, especially for COVID-19 research.  After completion, these capabilities will be logged into the MSRDC’s system and matched to a potential government funded research program and MSI consortium member who would be the prime awardee.

The Consortium awards are “other transactions” rather than traditional grants or contracts.  These non-competed awards bypass solicitation, allowing for a direct connection between collaborative partners and government program managers.

Some Advantages – Skip The Line:

  • Access a community of researchers and partners
  • Leverage unique funding vehicles to secure direct, non-competed awards
  • Move your idea from concept to award in as few as 90 days, (or fewer)

If you would like to schedule a meeting with MSRDC to discuss the funding vehicle or have any questions, please send an email to:

info@msrdconsortium.org (All other inquiries)
busdev@msrdconsortium.org (For questions about working with our partners and member institutions)
awards@msrdconsortium.org (For those who already have an active research award)
membership@msrdconsortium.org (Questions about membership)

MSI STEM Research & Development Consortium

1275 K Street NW, Suite 850
Washington, DC 20005
Website: https://www.msrdconsortium.org
Hours: Monday to Friday, 9:00 am to 5:00 pm EST
Phone: (202) 684-7953

Also, please take the time to sign up to the MSRDC’s mailing lists for funding opportunities and news releases.

Please contact Anthony Smalls if you have any questions about the above.

Anthony Smalls, MBA
Program Manager
Research Operations & Infrastructure
Icahn School of Medicine at Mount Sinai
New York, NY 10029
E: anthony.smalls@mssm.edu
P: 212.241.0640
C: 646.546.4925

MSRDC Innovation Prospectus
MSRDC Member Capabilities

The MSI STEM Research & Development Consortium (MSRDC) - Additional funding for COVID-19-related research

The Icahn School of Medicine at Mount Sinai (ISMMS) is embarking upon an exciting diversity initiative, which will provide researchers with additional funding for COVID-19-related research, as well as research in other areas. The MSI STEM Research & Development Consortium (MSRDC) provides a unique funding mechanism for organizations and institutions to work with Minority-Serving Institutions (MSI), such as Historically Black Colleges & Universities (HBCUs), etc., on government projects. MSIs join the Consortium as members, while non-MSIs (i.e., institutions of higher education other than MSIs, such as ISMMS) join as “Consortium Collaborators.” These entities, along with the sponsoring government agencies, form a non-traditional collaborative partnership. Once institutions are a part of the Consortium, any member of the faculty can use this procurement vehicle, as it is not solely for use by one person, lab, or group.

The Consortium awards are “other transactions” rather than traditional grants or contracts. These non-competed awards bypass solicitation, allowing for a direct connection between collaborative partners and government program managers. Consequently, this mechanism creates the opportunity for rapid procurement of funds (i.e., 90-120 days), as the partners work together to produce a Scope of Work (SOW) and a Request for Proposal (RFP). There are no communicative blackout periods with government program managers.

MSRDC’s process is as follows: (1) MSRDC collects proposals from members and collaborators and submits those to the Government Research Partners. Due to the nature of the MSRDC Cooperative Agreement, the Consortium works directly with these partners to set deadlines and determine other project details. There is no floor or ceiling regarding the funding amount. The investigators propose budgets for the research.

Since 2016, MSRDC has accumulated $15 million in research, $3 million in researcher support, $2.2 million in partner support, and $1.5 million in equipment funding. As research is conducted, the collaborative partners submit invoices to the MSRDC, which, in turn, disseminates the awarded funds.

Some of the Government Research Partners includes:

  • Department of Defense (DoD)
  • Department of Education (DoE)
  • Homeland Security
  • Communications-Electronics Research Development Center (CERDEC)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Army Material Systems Analysts Activity (AMSAA)
  • Department of Transportation

As mentioned above, the current COVID-19 pandemic has generated funding opportunities in various research areas. If you are already conducting COVID-19-related research or are interested in beginning research in this area, there may be funding opportunities for you, your team, or your lab.

For further questions, please contact Anthony Smalls via email at Anthony.Smalls@mssm.edu, or visit the MSRDC Consortium website.

MSI STEM Research & Development Consortium
1275 K Street NW, Suite 850
Washington, DC 20005
Website: https://www.msrdconsortium.org
Hours: Monday to Friday, 9:00 am to 5:00 pm EST
Phone: (202) 684-7953
Email:
info@msrdconsortium.org
busdev@msrdconsortium.org (For questions about working with our partners and member institutions)
awards@msrdconsortium.org (For those who already have an active research award)

Additional background information about MSRDC.

MSHS Guideline for Deans Funding for COVID-19 Research

Send one page proposals, biosketch, and budget—as one PDF—to covidpilotgrants@mssm.edu.

NOT-CA-20-080 - Request for Information (RFI): Seeking Stakeholder Input on Scientific Gaps and Research Needs Related to Delivery of Cancer-related Care via Telehealth

Notice Number: NOT-CA-20-080

The National Cancer Institute (NCI) is seeking information on scientific gaps and research needs related to the delivery of cancer-related care via telehealth. This request for information (RFI) is part of a planning effort designed to identify promising opportunities and set priorities for research in this area.

More Information

NOT-HD-20-017 - Notice of NICHD Participation in NOT-EB-20-012 "Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)"

Notice Number: NOT-HD-20-017

The purpose of this Notice is to inform potential applicants that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is participating in NOT-EB-20-012 “Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)”.

More Information

NOT-MH-20-061 - Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-MH-20-061

The purpose of this Notice is to extend the data-harmonization effort at the National Institute of Mental Health (NIMH) announced in NOT-MH-15-009 to research protocols pertaining to the public health emergency caused by Coronavirus Disease 2019 (COVID-19), the disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

NIMH has already made a significant investment in a data repository to hold human subjects data related to mental illness and related fields. This repository allows data from multiple sources to be aggregated and easily accessed by the research community. However, the data repository is most useful when research laboratories collect data using the same set of data elements. With this Notice, NIMH offers guidance on the use of consensus-derived common data elements (CDEs) pertaining to mental health outcomes that were previously discussed in NOT-MH-15-009and a set of newly available measures regarding experiences during the COVID-19 public health emergency and exposures to the SARS-CoV-2 virus (the virus that causes COVID-19). The goal of this Notice is to reduce proliferation of one-off survey items and to facilitate data integration, collaboration, and comparisons across data sets.

More Information

Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis

Notice Number: NOT-CA-20-054

The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.

More Information

Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19

Notice Number: NOT-HS-20-008

Agency for Healthcare Research and Quality (AHRQ) intends to publish a new funding opportunity announcement using the R01 mechanism to support novel, high-impact studies evaluating health system and healthcare professional responsiveness to COVID-19.  This Notice is being provided to allow potential applicants sufficient time to develop responsive applications.

More Information

Notice of Participation of National Institute of Nursing Research (NINR) in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional")

Notice Number: NOT-NR-20-005

The purpose of this Notice is to inform applicants that the National Institute of Nursing Research (NINR) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)

  • NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
  • NSF encourages the research community to respond to this challenge through existing funding opportunities.
  • In addition, NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to rapid-covid19@nsf.gov.
  • Complete guidance on submitting a RAPID proposal may be found in Chapter II.E.1 of the NSF Proposal and Award Policies and Procedures Guide.

More Information

NIH Administrative Supplements

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC’s web site to ensure they meet the IC’s requirements.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.

Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA.

More Information

Notice of Changes to Funding Opportunities

NOT-OD-20-140 - Notice of Corrections to RFA-OD-20-013 "Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)" Budget and Review

Notice Number: NOT-OD-20-140

The purpose of this notice is to inform potential applicants of corrections to the budget and review of RFA-OD-20-013 Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional).

More Information

NOT-AG-20-036 - Notice of NIA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-AG-20-036

This Notice informs potential applicants that the National Institute on Aging (NIA) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional).”

More Information

NOT-DA-20-061 - Notice of NIDA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-DA-20-061

The purpose of this Notice is to inform potential applicants that the National institute of Drug Abuse (NIDA) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-DC-20-010 - Notice of NIDCD's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-DC-20-010

The purpose of this Notice to inform potential applicants that the National Institute on Deafness and Other Communication Disorders (NIDCD) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional).”

More Information

NOT-OD-20-111 - Notice of ORWH Participation in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”

Notice Number: NOT-OD-20-111

The purpose of this Notice is to inform potential applicants that the Office of Research on Women’s Health (ORWH) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-MH-20-064 - Notice of NIMH Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-MH-20-064

The purpose of this Notice is to inform potential applicants that the National Institute of Mental Health (NIMH) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-DK-20-026 - Notice of Additional Activity Code Accepted for "NOT-DK-20-018, Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK"

Notice Number: NOT-DK-20-026

The purpose of this Notice is to add the U24 activity code to the activity codes eligible for submissions and adjust the language for parent awards to be eligible under NOT-DK-20-018: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK.

More Information

NOT-AA-20-007 - Notice of Participation of NIAAA in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional"

Notice Number: NOT-AA-20-007

The purpose of this Notice is to inform applicants that the National Institute on Alcohol Abuse and Alcoholism (NIAAA) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-CA-20-048 - Notice of National Cancer Institute (NCI) Participation in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Notice Number: NOT-CA-20-048

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in PA-18-935, “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional).”

More Information

NOT-DC-20-003 - Notice of NIDCD's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-DC-20-003

The purpose of this Notice is to inform applicants that the National Institute on Deafness and Other Communication Disorders (NIDCD) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”. The following changes and updates are made to PA-18-935 (shown in italics) to reflect NIDCD’s participation in this funding opportunity announcement (FOA).

More Information

NOT-HG-20-034 - Notice of NHGRIs Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-HG-20-034

The purpose of this Notice is to inform applicants that the National Human Genome Research Institute (NHGRI) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”.

More Information

NOT-MD-20-018 - Notice of Participation of the National Institute on Minority Health and Health Disparities (NIMHD) in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Notice Number: NOT-MD-20-018

The purpose of this Notice to inform potential applicants that the National Institute on Minority Health and Health Disparities (NIMHD) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional).”

More Information

NOT-TR-20-015 - Notice of NCATS' Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-TR-20-015

The purpose of this Notice is to inform applicants that the National Center for Advancing Translational Sciences (NCATS) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”.

More Information

Request for Proposal

NOT-CA-20-077 - Request for Proposals (RFP) Solicitation S20-119: Serological Sciences Network Capacity Building Centers

Notice Number: NOT-CA-20-077

Leidos Biomedical Research, Inc. (Leidos Biomed) has issued an RFP for Capacity Building Centers to support the Serological Sciences Network (SeroNet), developed to mobilize collaborative efforts to develop serological assays of high specificity and high sensitivity for deployment to test for SARS-CoV-2 induced immune responses and to rapidly expand national serological testing capacity.

More Information

NIH NOSI (Notice of Special Interest)

NOT-LM-20-011 - Notice of Special Interest (NOSI): Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)

Notice Number: NOT-LM-20-011

NLM is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for innovative high-risk/high impact research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NLM’s strategic goal of fostering data driven research.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

NOT-HL-20-782 - Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials

Notice Number: NOT-HL-20-782

NHLBI is issuing this Notice of Special Interest (NOSI) due to the urgent need for early phase clinical trials to evaluate new or existing interventions that may prevent or treat Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

NOT-AT-20-011 - Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AT-20-011

NCCIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

NOT-EB-20-003 - Notice of NIBIB's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-EB-20-003

The purpose of this Notice is to inform applicants that the National Institute of Biomedical Imaging and Bioengineering (NIBIB) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

08/08/2020 - NOT-OD-20-121 - Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

Notice Number: NOT-OD-20-121

This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Expiration Date: Aug 8, 2020

More Information

08/14/2020 - NOT-CA-20-082 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-CA-20-082

Through this Notice of Special Interest (NOSI), the National Cancer Institute (NCI) announces an opportunity for current NCI funded Principal Investigators whose postdoctoral fellows have temporarily lost stipend support from a non-profit funder because of the COVID-19 global pandemic may apply for an administrative supplement to cover the postdoctoral fellow’s salary plus applicable F&A for the time and effort devoted to the NCI funded grant.

Expiration Date: August 14, 2020

More Information

09/09/2020 - NOT-OD-20-119 - Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

Notice Number: NOT-OD-20-119

This Notice of Special Interest (NOSI) highlights the urgent need to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing among underserved and/or vulnerable populations across the United States through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Expiration Date: Sept 9, 2020

More Information

09/09/2020 - NOT-OD-20-120 - Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

Notice Number: NOT-OD-20-120

This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Expiration Date: Sept 9, 2020

More Information

10/06/2020 - NOT-HL-20-757: Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-HL-20-757

NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

First Available Due Date: March 17, 2020
Expiration Date: October 06, 2020

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

10/17/2020 - NOT-TR-20-012: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Notice Number: NOT-TR-20-012

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

First Available Due Date: June 05, 2020
Expiration Date: October 17, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

11/10/2020 - NOT-EB-20-008 - Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-EB-20-008

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications from current grantees to develop life-saving technologies that can be ready for commercialization within one to two years.

Expiration Date: November 11, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

12/30/2020 - NOT-MD-20-022 - Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations

Notice Number: NOT-MD-20-022

NIH-designated U.S. health disparity populations: Racial and ethnic minorities, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities (see https://www.nimhd.nih.gov/about/overview/).

COVID-19 vulnerable populations: Residents of chronic care and assisted living facilities; community-dwelling older adults; individuals with cognitive impairment or dementia; homeless populations; incarcerated populations and those involved with the criminal justice system (e.g., participants of re-entry programs); adults with medical comorbidities; pregnant women; children and adolescents; individuals with substance use disorders or severe mental illness, those living in congregate housing (e.g., shelters, residential treatment or assisted living); persons who are deaf or with disabilities including visual, hearing, communication, or mobility impairment; detainees in immigration centers; migrant communities; individuals living on tribal lands or reservations; and communities that are exposed to high rates of air pollution or other toxic exposures. Vulnerable groups also include those on the frontlines of healthcare during the COVID-19 pandemic, and those working in essential business operations (e.g., grocery and pharmacy workers, transportation, hospital and community janitorial/sanitation workers, waste collectors, postal and other delivery services, warehouse personnel, etc.).

Multilevel Intervention: An intervention at two or more levels of influence, including policy (governing bodies or others who establish policies, rules, or guidelines), community (a group of people living in a defined geographic area or having particular characteristics in common, structural, and/or environmental determinants of health), organizational (large healthcare systems, community health clinics, public health organizations, community-based organizations, social services, schools, workplaces, other service providers, etc.), interpersonal (e.g., communication, social supports, relationships with others), and individual (e.g., community residents, employees, caregivers, family members, providers;). See the NIMHD Research Framework, https://www.nimhd.nih.gov/about/overview/research-framework.html, for examples of health determinants at different levels of influence).

Expiration Date: Dec 30, 2020

More Information

12/30/2020 - NOT-MH-20-053 - Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19

Notice Number: NOT-MH-20-053

This Notice of Special Interest (NOSI) highlights interest in research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. While the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact.

Expiration Date: Dec 30, 2020

More Information

2021 NIH NOSI (Notice of Special Interest)

02/06/2021 - NOT-GM-20-025: Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Notice Number: NOT-GM-20-025

NIGMS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19

First Available Due Date: March 25, 2020
Expiration Date: February 06, 2021

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

03/21/2021 - NOT-DA-20-047: Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

Notice Number: NOT-DA-20-047

NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

First Available Due Date: March 19, 2020
Expiration Date: March 31, 2021

More Information

03/25/2021 - NOT-AI-20-034: Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AI-20-034

NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

First Available Due Date: March 25, 2020
Expiration Date: March 25, 2021

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

NOT-AI-20-058 - Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)”

Notice Number: NOT-AI-20-058

The purpose of this Notice is to inform the extramural community that NOT-AI-20-034, “Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)” is rescinded effective immediately. NOT-AI-20-034 is replaced by NOT-AI-20-059 which highlights very specific needs for competitive revision applications to NIAID grants to facilitate the Federal SARS-CoV-2/COVID-19 research response.

Release Date: July 6, 2020

More Information

03/31/2021 - NOT-EB-20-006 - Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-EB-20-006

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years.

Expiration Date: March 31, 2021

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

03/31/2021 - NOT-EB-20-007 - Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-EB-20-007

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years.

Expiration Date: March 31, 2021

The NOSI is not a funding opportunity in itself. You must apply to the approrpiate Administrative Supplement and include the NOSI #.  Please read the NOSI for complete information.

More Information

04/01/2021 - NOT-OD-20-097- Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

Notice Number: NOT-OD-20-097

This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.

Release Date: April 13, 2020
First Available Due Date: April 13, 2020
Expiration Date: April 01, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

April 15, 2021 - NOT-NS-20-051 - Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

Notice Number: NOT-NS-20-051

NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Release Date: April 30, 2020
First Available Due Date: May 01, 2020
Expiration Date: April 15, 2021

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

04/16/2021 - NOT-MH-20-047 -Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus

Notice Number: NOT-MH-20-047

NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

Expiration Date: April 16, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

04/16/2021 - NOT-AA-20-011 - Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA

Notice Number: NOT-AA-20-011

The impact of the COVID-19 pandemic on the nation is vast, especially on health and well-being. Research suggests that alcohol consumption tends to increase during times of duress and uncertainty such as disasters and other traumatic events, and as such alcohol is often misused to cope with stress, anxiety, and other uncomfortable emotions. In addition, the misuse of alcohol to cope with the stress as a result of physical distancing and other policy measures, and a lack of access to supportive social networks and treatment for people with pre-existing alcohol use disorder (AUD) are significant concerns during the pandemic. These outcomes are particularly challenging with respect to COVID-19 because alcohol misuse can interfere with normal immune system function and elevate susceptibility to viral infections of the respiratory system. Alcohol-associated damage to the liver, heart, and other organs may also complicate health outcomes in individuals with COVID-19. These myriad physical and behavioral health outcomes related to alcohol and COVID-19 present a range of urgent research needs and opportunities.

Release Date: April 16, 2020
First Available Due Date: May 15, 2020
Expiration Date: April 16, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

05/01/2021 - NOT-AG-20-022 - Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AG-20-022

NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

05/01/2021 - NOT-MD-20-019 - Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities

Notice Number: NOT-MD-20-019

The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

Expiration Date: May 01, 2021

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

05/04/2021 - NOT-ES-20-015 - NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-ES-20-015

NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

Expiration Date: May 04, 2021

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

07/02/2021 - NOT-AI-20-059 - National Institute of Allergy and Infectious Diseases/NIH/DHHS - Notice of Special Interest (NOSI): Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NIAID is issuing this Notice of Special Interest (NOSI) to highlight very specific and limited needs for Competitive Revision applications to active NIAID grants in order to further build the infrastructure that NIAID needs to support the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) research response. This NOSI replaces NOT-AI-20-034 which was rescinded with this issuance of this Notice.

Expiration Deadline: July 2, 2021

More Information

07/10/2021 - NOT-TR-20-011: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Notice Number: NOT-TR-20-011

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

First Available Due Date: May 04, 2020
Expiration Date: July 10, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

07/13/2021 - NOT-OD-20-129 - Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project

Notice Number: NOT-OD-20-129

NIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. Because many people with Down syndrome are at increased risk of having co-occurring medical conditions, such as pulmonary disease, cardiac problems, obesity, diabetes, sleep apnea, and altered immune function that may predispose them to more severe infection with SARS-CoV-2, they may be particularly vulnerable to COVID-19 complications. Combined with shared living situations, and reduced access to testing and treatment services due to disparities in provision of resources, the impact of COVID-19 infection in people with Down syndrome is likely to be elevated. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.

More Information

2022 NIH NOSI (Notice of Special Interest)

01/26/2022 - NOT-TR-20-016 - Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

Notice Number: NOT-TR-20-016

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Expiration Date: January 26, 2022

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

01/26/2022 - NOT-TR-20-017 - Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus

Notice Number: NOT-TR-20-017

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Expiration Date: January 26, 2022

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

09/08/2022 - NOT-DC-20-008 - Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders

Notice Number: NOT-DC-20-008

Coronavirus Disease 2019 (COVID-19) is a recently emerged human disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is a paucity of data on the impact of SARS-CoV-2 on the sensory and communicative functions within the scientific mission areas of NIDCD. NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

Expiration Date: Sept 8, 2022

More Information

2023 NIH NOSI (Notice of Special Interest)

04/02/2023 - NOT-MH-20-040 - NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training (Admin Supp Clinical Trial Optional)

Notice Number: NOT-MH-20-040

The purpose of the NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training is to support advanced research opportunities for exceptional individuals holding the MD/PhD degree who are early in their research careers and thereby help these individuals transition efficiently and effectively from the period of clinical training to the next stage of their research careers. This administrative supplement program will provide focused, protected research time for eligible individuals during residency and/or clinical fellowship. The proposed research experience must have the potential to contribute significantly to the candidate’s research career.

Release Date: April 14, 2020
First Available Due Date: April 01, 2021
Expiration Date: April 02, 2023

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

2024 NIH NOSI (Notice of Special Interest)

01/28/2024 - NOT-DA-20-058 - Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders

Notice Number: NOT-DA-20-058

There is an urgent need for remotely delivered Substance Use Disorder (SUD) treatments to reduce patient burden and for methods to conduct clinical trials remotely. The purpose of this NOSI is to stimulate research to evaluate the safety and efficacy of telemedicine or remotely provided treatments for SUD, and to develop tools for remote collection of data in clinical trials of treatments for SUD.

Release Date: June 29, 2020
First Available Due Date: October 05, 2020
Expiration Date: January 08, 2024

More Information

Continuous Submission

AIDS United - Relief, Recovery and Resilience Fund

AIDS United is making funds available, through this request for applications, to assist in meeting the needs of organizations serving people living with and at risk for HIV and AIDS, and that are experiencing challenges meeting their community’s needs because of the COVID-19 pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Adira Foundation - Fast-Track Grant Response: COVID-19

As people all over the world are joining together to slow the spread of the coronavirus and its impact on daily life—an effort that changes daily and differs city to city and state to state—Adira Foundation is redirecting some funding to meet immediate and pressing need in our community.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

American College of Chest Physicians - CHEST Foundation COVID-19 Community-based Grant

As the charitable foundation for the American College of Chest Physicians, the CHEST Foundation has a mission of championing lung health by supporting clinical research, patient education, and community service. During this time of need, the CHEST Foundation is focusing efforts on assisting those making a difference in their communities during the COVID-19 pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Biogen - COVID-19 Response Program

The Biogen Foundation has committed $10M to aid in COVID-19 relief efforts around the world. At this time, the Biogen Foundation’s COVID-19 relief efforts are focused on the following categories: expanding and ensuring access to testing; easing the burden on healthcare systems and healthcare workers; and providing food and necessities for our most vulnerable populations.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Bloomberg Philanthropies - Coronavirus Local Response Initiative

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Brookhaven National Laboratory - COVID-19 Research Support

The Center for Biomolecular Structure team is supporting remote macromolecular crystallography experiments at Beamlines 17-ID-1 (AMX) and 17-ID-2 (FMX) for research projects related to COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Brooklyn Community Foundation - Brooklyn COVID-19 Response Fund

Funding Amount: $10,000

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Call for Expert Collaborators: COVID-19 Response

Crowdhelix is seeking researchers & innovators worldwide with a strong track record of excellence in fields relevant to the global effort to tackle the novel coronavirus (COVID-19) pandemic. The sponsor is offering free access to Crowdhelix, their online Open Innovation platform, to experts seeking to collaborate across continents and disciplines in developing R&D funding proposals to help tackle COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 Early Treatment Fund (CETF) - Grants Program

CETF will be funding initiatives that focus on treating outpatients with COVID-19 to prevent hospitalization. Grant recipients are required to share what they learn with others.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 Fast Track Access

To facilitate research on COVID-19, CERIC has set up a dedicated Fast Track Access to a selected number of instruments including 600 and 800 MHz NMR, SAXS light scattering laboratory, Cryo EM, synchotron beamlines for Small Angle X-ray scattering and X-ray diffraction, and Synchroton Infrared Source for Spectroscopy and Imagine. Due to the travel restrictions in place for several countries, remote access will be preferred.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 HPC Consortium

The COVID-19 HPC Consortium encompasses computing capabilities from some of the most powerful and advanced computers in the world. XSEDE hopes to empower researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections. Consortium members manage a range of computing capabilities that span from small clusters to some of the very largest supercomputers in the world.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 Relief Fund

Robin Hood anticipates making grants to 501(c)(3) organizations in New York City that are well-positioned to serve low-income communities. The initial grants, expected to last three months in duration, will average $45,000.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Diamond Light Source - Rapid Access Call for Proposals: SARS-CoV-2

As part of Diamond’s effort to combat COVID-19 (as demonstrated by the fragment screening campaign against SAR-CoV-2 Main protease), fragment screening expertise and infrastructure are offered to users working on Covid-19 related projects.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

European Synchrotron Radiation Facility - Covid-19 Scientific Research

The ESRF is ready to provide access to its facilities for Covid-19 related research projects. This exceptional access will be granted with the aim to contribute to the international scientific effort to overcome the covid-19 pandemic.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

European Synchrotron Radiation Facility - Mail-in Protein-to-Structure Services to Support Structural Biology Research Related to COVID-19 at the EMBL Grenoble HTX Lab and the Joint ESRF-EMBL MX Beamlines

The ESRF-EMBL Joint Structural Biology Group (JSBG) invite COVID-19 related proposals that can benefit from the seamless integration of the EMBL High throughput Crystallization Facility (HTX Lab) with the highly automated JSBG MX beamlines at the ESRF. The pipeline starts with mail-in samples and integrates crystallization screening, crystal optimization, ligand soaking if required and eventually fragment screening with libraries of up to 1200 fragments. Crystals obtained will be automatically harvested and passed to the ESRF for automated X-ray data collection, with real-time access to experimental results and parameters. This pipeline is uniquely suited to support of structural biology projects in conditions of confinement and restricted access to labs. The HTX lab is already accepting crystallization projects on COVID-19 related research and three ESRF beamlines (MASSIF-1 (ID30A-1), ID30B and ID23-2) will become operational after 11 May 2020.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Fast Grants

Emergent Ventures invites applications from scientists at academic institutions currently working on a COVID-19 related project and in need of funding. Fast Grants are $10,000 to $500,000 and decisions are made in under 48 hours.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Federal Communications Commission - COVID-19 Telehealth Program

The COVID-19 Telehealth Program will provide $200 million in funding, appropriated by Congress as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, to help health care providers provide connected care services to patients at their homes or mobile locations in response to the novel Coronavirus 2019 disease (COVID-19) pandemic.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Funeral Services Foundation - COVID-19 Crisis Response Fund

This fund is designed to be flexible and will provide grants for immediate needs including funeral service emergency response to significant loss of life, to organizations and resources providing service to families with unresolved and complicated grief due to loss during this crisis, and for other important needs of the funeral service profession and the families served. The Fund will consider proposals from US 501(c)3 nonprofit organizations and Canadian registered charities.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Ginkgo Bioworks - Access to Platform for Partner COVID-19 Projects

Ginkgo Bioworks has committed its platform to supporting research and development efforts for COVID-19, including $25M of free access to its infrastructure.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Global Innovation Fund Grant Program

The Global Innovation Fund was set up to confront global development challenges by funding innovations with the potential to improve the lives of the world’s poorest people. GIF will devote resources to new deals for COVID-19-related grantmaking in 2020.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

ICESCO prize for Fighting against Coronavirus

In response to the World Health Organization’s appeal to the international community to “seize every opportunity to curb, contain, combat, and delay the spread of the virus, and mitigate its impact”, the Islamic World Education, Scientific, and Cultural Organization (ICESCO) announces its Prize for Fighting Novel Coronavirus (COVID-19). The amount of the prize is US$200,000, including an award medal.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Innovations for Poverty Action - Competitive Fund for Peace and Recovery

Submission Deadline Not Posted

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Jacob and Valeria Langeloth Foundation - COVID-19 Rapid Response Fund

The Jacob and Valeria Langeloth Foundation created the COVID-19 Rapid Response Fund (CRRF) to enable Langeloth to address organizations’ urgent and critical needs that have arisen due to the COVID-19 global pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

National Institute of Allergy and Infectious Diseases/NIH/DHHS - Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)

The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS - Rapid Acceleration of Diagnostics (RADx): Fast-Track Program for COVID-19 Test Development and Distribution

National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)

07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021

National Institute of Biomedical Imaging and Bioengineering (NIBIB) invites applications for exploratory/developmental research programs of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). hese studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Research Project Grant (R01 Clinical Trial Required)

07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021

NIH invites applications for discrete, specified, circumscribed projects in areas representing the specific interests and competencies of the investigator(s). This NIBIB Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of the NIBIB. For this Funding Opportunity Announcement, NIBIB will only support R01 applications proposing early-stage clinical trials through Phase I, first-in-human, safety, feasibility or other small clinical trials that inform early-stage technology development. NIBIB will not support applications proposing Phase II, III, IV or pivotal clinical trials or trials in which the primary outcome is efficacy, effectiveness or a post-market concern. This FOA will use the NIH Research Project (R01) award mechanism.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022, 16-Feb-2022, 07-May-2022, 16-Jun-2022, 07-Sep-2022, 16-Oct-2022, 07-Jan-2023
This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data.

A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal.All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

Application Deadlines: 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Application Deadlines: 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.   This Funding Opportunity Announcement does not accept applications proposing clinical trial(s

Application Deadlines: 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 05-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Novartis Foundation - COVID-19 Community Response Fund

In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million over a one-year period for immediate response and recovery efforts related to the pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Mercatus Center - COVID-19 Response: A Call for Ideas

The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Mozilla Open Source Support (MOSS) Awards Program - COVID-19 Solutions Fund

Mozilla will provide awards of up to $50,000 each to open source technology projects which are responding to the COVID-19 pandemic in some way.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Open Road Alliance - Response to COVID-19

Open Road is offering charitable grants and loans to nonprofits and social enterprises impacted by COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Open Call for Innovation Focus Area: COVID-19: Rapid Sanitising Technology

In addition to its regular Open Call, DASA publishes Open Call innovation focus areas to increase awareness of some of the enduring challenges faced by defence and security stakeholders, and to stimulate the submission of relevant innovative proposals.

For the current focus area: COVID-19: Rapid Sanitising Technology, DASA is looking to identify, develop and demonstrate rapid sanitising technologies for ambulances that have transported a patient with suspected COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Pollination Project - COVID-19 Rapid Response Grants

As of March of 2020, The Pollination Project has redirected all of our focus, support, and seed funding to uplifting the selfless actions of frontline grassroots volunteers working in response to COVID-19 (aka coronavirus) in their communities. Now until it is no longer needed, The Pollination Project will accept applications for volunteer community projects that address: direct needs around water, sanitation, and hygiene; community & emotional resilience; and virtualization of existing grassroots projects.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Pioneering Ideas: Exploring the Future to Build a Culture of Health

The Robert Wood Johnson Foundation (RWJF) has issued a call for proposals, “Pioneering Ideas: Exploring the Future to Build a Culture of Health”, seeking proposals that are primed to influence health equity in the future. They are interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, they welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Priority Access Call for Work on Combating COVID-19

The Paul Scherrer Institute (PSI) has opened a “PRIORITY COVID-19 Call” for short proposals and quick peer review to enable rapid access to beamtime. Research proposals shall have the potential to effectively contribute to the understanding of the COVID-19 virus and/or to improve the clinical or public health response and patient care.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Rapid Access Call for Proposals: SARS-CoV-2

Diamond Light Source are offering priority rapid access for groups who require instrument time for projects directly related to SARS-CoV-2 viral proteins.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Rapid Response Funding for Covid-19

Omidyar Network India has announced a call for proposals for rapid response funding to tackle the challenges posed by the Covid-19 situation and the consequent socio-economic impact. Proposals that strengthen containment, detection and treatment, support crisis management capabilities, and enhance resilience and recovery in the wake of Covid-19 are welcomed. They are committing Rs. 7.5 crore (US $1 million) to this initiative.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)

01-May-2020, 01-Jun-2020, 01-Jul-2020, 03-Aug-2020, 01-Sep-2020, 01-Oct-2020, 02-Nov-2020, 01-Dec-2020, 04-Jan-2021, 01-Feb-2021, 01-Mar-2021, 01-Apr-2021, 03-May-2021, 01-Jun-2021, 01-Jul-2021, 02-Aug-2021, 01-Sep-2021, 01-Oct-2021, 01-Nov-2021, 01-Dec-2021, 03-Jan-2022, 01-Feb-2022, 01-Mar-2022, 01-Apr-2022, 02-May-2022, 01-Jun-2022, 01-Jul-2022, 01-Aug-2022, 01-Sep-2022, 03-Oct-2022
This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

SARS-COV-2 Diagnostics: Performance Data

FIND is conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays. To complement these evaluations, and in partnership with WHO in line with the sponsor’s official Collaborating Centre remit, the sponsor is endeavouring to centralize the collection of SARS-CoV-2 diagnostic performance data as a global public good. FIND is working closely with partners including the World Health Organization (WHO) in support of the global effort to combat the COVID-19 pandemic. In this respect, FIND is curating the overall diagnostic pipeline and tracking reported global diagnostic use, as well as conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Social Science Research Council - Just Tech Covid-19 Rapid-Response Grants

The Social Science Research Council (SSRC), as part of its Just Tech program, seeks proposals from across the social sciences and related fields that address the risks, opportunities, and challenges posed by public health surveillance stemming from the Covid-19 pandemic. The sponsor specifically encourages proposals that interrogate the role the public and private sectors may play in mitigating or exacerbating the health crisis, the effects of which are already unevenly distributed.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Staunton Farm Foundation - Emergency Fund for the COVID19 Pandemic

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

TechWatch Meeting Request

The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Turkish Philanthropy Funds - TPF COVID-19 Community Relief Fund

The sponsor has created the COVID-19 Community Relief Fund to support containment, response and recovery activities for those affected and for the responders.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Wellcome Trust - Epidemic Preparedness: COVID-19 Funding Call

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

West Coast Consortium for Technology & Innovation in Pediatrics - 2020 COVID-19 FlexGrants

The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is announcing a limited grant opportunity to support pediatric medical device innovators who are able to use their technology to aid in the current COVID-19 pandemic. Companies will be awarded grants up to $15,000 to support activities that apply or adapt their existing medical device to help manage the health impacts of the crisis on children. Medical devices with adult indications that are expanding or wish to expand their clinical indication to pediatrics are welcome to apply.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

July 2020 Application Deadlines

07/17/2020 - American College of Chest Physicians - CHEST Foundation Research Grant in COVID-19

The CHEST Foundation, as the charitable foundation for the American College of Chest Physicians, has a mission of championing lung health by supporting clinical research, patient education, and community service. The Foundation is accepting proposals for research projects that address clinical (hospital or outpatient) or community-related aspects of COVID-19.

Application Deadline: July 17, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

07/20/2020 - National Institutes of Health/DHHS - Announcement for Serological Sciences Centers of Excellence

This Notice is associated with the COVID-19 Supplemental funding through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH “to develop, validate, improve, and implement serological testing and associated technologies.” The National Cancer Institute (NCI) intends to publish a Funding Opportunity Announcement (FOA) as a Request for Applications (RFAs) to solicit applications to establish Serological Sciences Centers of Excellence of collaborating investigators and an RFA for research projects. Specifically, both the Centers and the projects will identify and advance research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection, especially as it relates to cancer patients.

Application Deadline: July 20, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

07/22/2020 - RFA-CA-20-038 - Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH “to develop, validate, improve, and implement serological testing and associated technologies “. The purpose of the FOA is to establish Serological Sciences Centers of Excellence with the goal of identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing.  These U54 Centers will be part of a Serological Sciences Network (SeroNet). Other components of the Network will include Serological Sciences Research Projects (U01), the FNLCR Serology Laboratory, Serological Capacity Building Centers (CBC) and a Serological Sciences Network Coordinating Center (SSNCC) which will be managed through Frederick National Lab for Cancer Research (FNLCR), a Federally Funded Research and Development Center. It may also include SBIR grants and other grants and contracts related to serology associated with SARS-CoV-2. All components are expected to collaborate across the entire Network, sharing data, results, and reagents.

This FOA solicits multi-component U54 Center applications, whereas the companion FOA, RFA-CA-20-039, solicits applications for discrete U01 research projects. Successful applicants from both FOAs will become members of the Serological Sciences Network.

Application Deadline: July 22, 2020

More Information

07/22/2020 - RFA-CA-20-039 - Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH “to develop, validate, improve, and implement serological testing and associated technologies.” The purpose of the FOA is to establish Serological Sciences Research Projects with the goals of: identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; and determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. These U01 Research Projects will be part of a Serological Sciences Network (SeroNet). Other components of the Network will include Serological Sciences Centers of Excellence (U54), the FNLCR Serology Laboratory, Serological Capacity Building Centers (CBC), and a Serological Sciences Network Coordinating Center (SSNCC), which will be managed through the Frederick National Lab for Cancer Research (FNLCR), a Federally Funded Research and Development Center. It may also include SBIR grants and other grants and contracts related to serology associated with SARS-CoV-2. All components are expected to collaborate across the entire Network, sharing data, results, and reagents.

This FOA solicits U01 research project applications, whereas the companion FOA, RFA-CA-20-038, solicits multi-component U54 Centers applications. Successful applicants from both FOAs will become members of the Serological Sciences Network.

Application Deadline: July 22, 2020 (no late applications will be accepted)

More Information

07/23/2020 - RFP -- AMENDMENT -- Clinical Trial Materials for Virus Vaccines

Background and Introduction The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) is dedicated to improving global human health through the rigorous pursuit of effective vaccines for human diseases. One of the key components of NIAID’s mission involves the rapid advancement of promising vaccine candidates from the laboratory to the clinic. The Division of Intramural Research (DIR) within NIAID has a long history of studying the etiology and pathogenesis of infectious viral diseases, and of developing effective means of preventing or treating these diseases. NIAID DIR has advanced to clinical trials multiple vaccine candidates, including both live-attenuated and inactivated virus formats. These formats have several advantages, including the ability to elicit a strong immune response with only one administration of vaccine. A primary objective of DIR remains the development of safe and effective vaccines against several disease-causing viruses including influenza, respiratory syncytial virus (RSV) and related pediatric respiratory viruses, dengue virus (DENV), and West Nile virus (WNV). In recent years, one of the major areas of DIR’s continuing research is the development of live-attenuated vaccine candidates effective against newly identified or emerging viruses, such as Zika virus (ZIKV) or the virus that causes COVID-19 (SARS-CoV-2). The capability to rapidly advance candidates for emerging viruses into clinical testing is now a critical component for NIAID DIR’s mission. This acquisition is for a single-award, Indefinite Delivery/Indefinite Quantity (IDIQ) contract that will be funded on a Task Order (TO) basis. The purpose of this acquisition is to establish an appropriate current Good Manufacturing Practice (cGMP) Contract Manufacturing Organization (CMO) to support rapid vaccine development by manufacturing vaccine Clinical Trial Materials (CTM) for trials of live-attenuated virus or inactivated virus vaccine candidates. cGMP is a Food and Drug Administration (FDA) regulation. Vaccine ancillaries or other biologics required to advance to clinical trials, such as virus challenge stocks, diluents, cell lines for use in the production of the vaccines, test materials, etc., are also within scope. The CMO shall have capability to produce viruses in both cell culture and specific-pathogen-free (SPF) eggs at scale appropriate for Phase 1 and 2 clinical trials. Based on extensive history, NIAID has existing processes for manufacturing the virus suspensions (candidate vaccine or challenge stock lot). The Contractor will produce, purify, process, fill, and flash freeze the virus suspensions as directed by NIAID, including any needed process qualifications. All activities required to comply with aseptic cGMP production and product management such as documentation, testing, storage, shipping, stability testing, etc. will also be required as specified under the Statement of Work and associated Task Orders. The contract will support work components in the following areas: Production of Virus Suspensions in Cell Culture Production of Influenza Virus Suspensions in the Allantoic Cavity of Embryonated Eggs Production of Qualified Cell Lines Process Development. Qualification of other vaccine components. For this solicitation, the NIAID requires proposals to be submitted via Online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov and then click on “How to Submit.” To submit online using eCPS, offerors must have a valid NIH electronic Research Administration (eRA) Commons account, which provides authentication and serves as a vehicle for secure transmission of documents and communication with the NIAID.

Application Deadline: July 23, 2020

More Information

07/31/2020 - National Center for Emerging and Zoonotic Infectious Diseases/CDC/DHHS - Improving Clinical and Public Health Outcomes through National Partnerships to Prevent and Control Emerging and Re-Emerging Infectious Disease Threats

Through this Notice of Funding Opportunity (NOFO), CDC will continue to protect America from health, safety and security threats, both foreign and in the U.S. This NOFO supports NCEZID’s strategic priorities to prevent the spread of infectious disease. This NOFO is intended to establish a roster of organizations that would be pre-identified and pre-approved for rapid funding to address emerging and re-emerging infectious disease threats through the program strategies. Organizations should have the capacity to reach frontline personnel to inform the development, adaptation, and use of guidance for infectious disease prevention and control. The organizations include, but is not limited to clinicians, other healthcare professionals, healthcare systems, and other organizations and institutions responsible for patient care and infectious disease prevention and control in the United States. This NOFO will establish an Approved-But-Unfunded (ABU) list of recipients, which will be used to effectively respond to public health threats. There is limited funding available at the time of this announcement. Additional funding will be contingent upon the availability of appropriations, at CDC’s sole discretion. CDC will provide additional information to ABU recipients, as public health needs arise.

LOI Deadline: July 14, 2020
Application Deadline: July 31, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

07/31/2020 - NORCAL Group Foundation - COVID-19 Relief & Response Campaign Grant

The Foundation is providing special grants to charitable organizations focused on Virtual Telehealth, Caregiver Counseling or Protective Equipment in their fight against the impact of COVID-19.

Application Deadline: July 31, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

07/31/2020 - Nurses House - COVID-19 Emergency Assistance

In response to the COVID-19 crisis Nurses House has established a grant program which is accepting applications from RNs, LPNs and LVNs who are infected with COVID-19, caring for a family member with COVID-19, or are under employer mandated quarantine due to COVID-19

Application Deadline: July 31, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

August 2020 Application Deadlines

08/03/2020 - Gilead Sciences - COVID-19 RFP Program: COMMIT

In an effort to further address the unmet medical need in COVID-19, Gilead Medical Affairs is launching the COMMIT program. The COMMIT program will support well defined individual projects.

LOI Deadline: August 3, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/03/2020 to 02/01/2021 - National Institute on Aging/NIH/DHHS - NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics In At-risk Older Adult Populations (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). Applications on the following priority topics are invited: Efficacy and safety of interventions that target aging-related biological mechanisms that may influence risk or severity of COVID-19 infection among at-risk older adults Efficacy and safety of preventive and treatment interventions in older patients with differing comorbid conditions that make them especially vulnerable to adverse outcomes of COVID-19 infection Effectiveness of health and/or custodial care practices to reduce transmission risk or improve outcomes of COVID-19 infection in nursing homes or other residential settings serving at-risk older persons, including the development and testing of infection control training procedures for healthcare workers Rapid pragmatic trials in (at least two) health systems, nursing homes, or adult living facilities, ensuring replication across large pragmatic trial sites and leveraging electronic health records to promote quality improvement in physician, hospital, palliative care, and hospice practices to improve outcomes for older patients with COVID-19, especially those with cognitive impairment, Alzheimer’s disease or Alzheimer’s disease-related dementias (AD/ADRD), or underlying comorbidities Trials in at-risk older adults age 65 and older for whom electronic medical records are available and long-term outcomes can be tracked, and in institutions serving those populations Trials in older adults with AD/ADRD, older adults from populations with NIH-defined health disparities, and/or other vulnerable populations (e.g. incarcerated, homeless, living in institutions) ?

Application Deadline: 03-Aug-2020 , 01-Sep-2020 , 01-Oct-2020 , 02-Nov-2020 , 01-Dec-2020 , 04-Jan-2021 , 01-Feb-2021

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/04/2020 - National Institutes of Health/DHHS - RFA-RM-20-021 -- NIH Director’s Emergency Early Independence Awards (DP5 Clinical Trial Optional)

This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Early Independence Award applications must be submitted in response to RFA-RM-20-014. The NIH Director’s Early Independence Award (a component of the High-Risk, High-Reward Research program of the NIH Common Fund) supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Early Independence Awards (through this FOA) or Transformative Research Awards (through RFA-RM-20-020) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual.

Application Deadline: August 4, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/05/2020 - Johnson (Robert Wood) Foundation - Systems for Action: Supplemental Research on COVID-19 Response and Recovery

Systems for Action (S4A) is a signature research program of the Robert Wood Johnson Foundation ?that helps to build the evidence base for a Culture of Health by rigorously testing new ways of connecting the nation’s fragmented medical, social, and public health systems. This call for proposals (CFP) will provide supplemental research funding to teams that are already engaged in the study of a promising system alignment mechanism, with the objective of learning how this mechanism performs in addressing health and social needs during the COVID-19 pandemic. Applicants responding to this CFP may apply for awards of 12 months or 24 months in duration and up to $100,000 per year in total costs to support supplemental studies that evaluate the implementation and impact of a system alignment mechanism in the context of the COVID-19 pandemic.

LOI Deadline (optional): July 20, 2020
Application Deadline: August 5, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/07/2020 - RFA-OD-20-013 - Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)

Funding Opportunity Number: RFA-OD-20-013

NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency cooperative agreement funding opportunity announcement (FOA) from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative, a consortium of community-engaged research projects to understand factors that have led to disproportionate burden of the pandemic on the underserved and/or vulnerable populations so that interventions can be implemented to decrease these disparities. This FOA seeks to fund a single Coordination and Data Collection Center (CDCC) as an integral part of the consortium. The funding for this supplement is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Application Deadline: August 7, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/10/2020 - Department of State - Boosting Frontline Health Workers’ Ability in Responding to COVID-19 - Virtual Awareness and Capacity Building Training Project

The U.S. Embassy in Cameroon announces an open competition for organizations to submit applications to support Cameroon’s COVID-19 response, focusing on increasing awareness, motivating informed and constructive action, supporting frontline medical workers, and/or countering misinformation. Awards may range from $10,000 to $40,000

Application Deadline: August 10, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/12/2020 - Tasmanian Community Fund - COVID 19 Response Fund - Support, Connect and Rebuild - Large

The Tasmanian Community Fund is calling for stage 1 applications ($100 000 to $500 000) for a range of community infrastructure projects. This year, the Fund calls for large applications that support Tasmanians and Tasmanian organizations to recover and rebuild from Covid19. The TCF is seeking applications across three streams:

  • Support – supporting and meeting the needs of vulnerable people to ensure they are not left behind as a result of Covid19
  • Connect – creating spaces and programs/processes to enable individuals and communities to reconnect and rebuild the social fabric of communities
  • Rebuild – providing individual and organizational capacity building including options for realigning work and directions for the “new normal” and beyond

LOI Deadline: August 12, 2020

Application Deadline: November 11, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/13/2020 - TD Banknorth Charitable Foundation - TD Ready Challenge

The TD Ready Challenge is an annual North American initiative, which supports organizations developing innovative solutions for a changing world. Recipients must be organizations that have impactful and measurable solutions focused on helping to open doors for a more inclusive and sustainable tomorrow. The COVID-19 pandemic has had an immense impact on society and that’s why this year, the sponsor has made the decision to focus the 2020 TD Ready Challenge on supporting innovative solutions that address the impacts of the pandemic.

Application Deadline: August 13, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/15/2020 - Department of the Air Force - JATF CSO COVID-19 Response

This announcement has been reissued to administratively update the solicitation number (previously FA3002-20-S0002) and highlight the CSO’s purpose for bolstering industrial capacity for domestic supplier base in support of JATF & HHS COVID-19 response priorities. All pending award determinations submitted under the previous solicitation number remain valid for government review and consideration.  This CSO announcement anticipates soliciting solution briefs through separate & periodically published Areas of Interest (AOI) to meet JATF & HHS COVID-19 response priorities; with an emphasis on Strategic National Sourcing strategy that seeks to strengthen direct or tangential domestic supplier sources, increase market resiliency/competition with a goal of bolstering the national industrial capacity for medical, pharmaceutical and/or other personal protective equipment. See attachments for full CSO and corresponding AOIs.

Application Deadline: August 15, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/18/2020 - VINNOVA - Innovation Projects in the Health Field that Dampen the Prevalence and Effects of the COVID-19 Pandemic

Health-related innovation projects and feasibility studies are funded within the call for proposal. These should help to curb the spread and effects of the covid-19 pandemic and prevent future pandemics. The results of the innovation projects should be implemented and utilized already during the ongoing pandemic, and the results of the feasibility studies will lead to increased preparedness for future pandemics.

Application Deadline: August 18, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/18/2020 - VINNOVA - Pre-Studies for Innovation Projects in the Health Area that Prevent Future Pandemics

Vinnova is accepting proposals for health-related innovation projects and feasibility studies that will help to curb the spread and effects of the COVID-19 pandemic and prevent future pandemics.

Application Deadline: August 18, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/20/2020, 12/02/2020, 03/02/2021 - PAR-20-243 - Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.

Application Deadline: 08/20/2020, 12/02/2020, 03/02/2021

More Information

08/25/2020 - Oak Ridge Institute for Science and Education - CDC COVID-19 Health Policy Fellowship

Six research opportunities are currently available with the Division of Birth Defects and Infant Disorders (DBDID) of the National Center on Birth Defects and Developmental Disabilities (NCBDDD) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.

Application Deadline: August 25, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/26/2020 - Tasmanian Community Fund - COVID 19 Response Fund - Support, Connect and Rebuild - Small Grants Program

The Tasmanian Community Fund will be calling for small, medium and large applications that support Tasmanians and Tasmanian organisations to recover and rebuild from Covid19. The Tasmanian Community Fund aims to support a broad range of projects and organisations. Up to $20,000 is available for small grants.

Application Deadline: August 26, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/27/2020 - National Institute of Corrections/Department of Justice - COVID 19 – Operational Challenges for Corrections

NIC’s seeking applications for funding under the Fiscal Year (FY) 2020 to support knowledge sharing around the nationwide correctional challenges that prisons, jails, and community services face during the COVID19 pandemic.

Application Deadline: August 27, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/31/2020 - Special Notice for Innovative Commercial Products In Support of CORONAVIRUS (COVID-19) Response

Special Notice for Innovative Commercial Products In Support of CORONAVIRUS (COVID-19) Response The Department of Homeland Security (DHS), Office of Procurement Operations (OPO) in support of Office of the Chief Procurement Officer will use the Commercial Solutions Opening Pilot Program (CSOP) procedures to acquire innovative, commercial items, technologies and services currently in the production/commercialization phase as well as adaptations of existing commercial products. The DHS Commercial Solutions Opening Pilot Program (CSOP) is a non- Federal Acquisition Regulation (FAR) based solicitation authority for acquiring innovative and commercial solutions. Section 880 of the National Defense Authorization Act (NDAA) for Fiscal Year 2017 (Pub. L. 114-328) authorized DHS to implement a pilot program to competitively procure innovative commercial items, technologies, and services using commercial solution opening procedures. CSOP is a new acquisition mechanism that provides a streamlined acquisition process and simplified contract terms that is designed to maximize efficiency and economy and minimize burdens and administrative costs for both the Government and industry. The Department of Homeland Security (DHS) efforts in preparedness and readiness have facilitated a speedy, whole-of-government response in confronting COVID-19, keeping Americans safe, and helping detect and slow the spread of the virus. DHS is seeking innovative commercial products that are in support of the COVID-19 response or similar microbial threats. Considering the magnitude and potential threat that COVID-19 and similar microbial threats pose to our nation’s health, safety and security, the Government seeks to rapidly accelerate the testing and fielding of new capabilities, employing innovative commercial products to the detection of exposure, prevention, containment and treatment of COVID-19 and similar microbial threats. Such innovative commercial products would be in support of the mission of the DHS, including the assistance that the FEMA is providing, in coordination with the HHS, to state, local, tribal, territorial governments and other eligible entities under the Stafford Act. Proposed innovative commercial products may be, but are not limited to, products that: 1) supplement shortages and/or emerging needs for personal protective equipment, 2) enhance or expedite screening capabilities, 3) enhance or expedite facility cleaning capabilities, 3) extend testing capabilities, 4) utilize technology to support the COVID-19 response, or 5) convert existing production and logistics operations to support the COVID-19 response. An important aspect of this objective is to support the efficient acquisition and testing of innovative commercial products from legitimate suppliers, as well as the efficient production and fielding of the successfully tested innovative commercial products. This notice will be updated with the General Solicitation describing the solicitation process and evaluation approach. The solicitation will be open and proposals accepted on an ongoing basis. The Government intends to make awards in Fiscal Year 2020. Potential submitters are hereby advised of the following: 1. The solicitation for innovative commercial products in support of COVID-19 is not a guarantee that award and obligation of funds will be made. 2. The costs incurred by companies in the preparation and submission of their response to solicitations will not be paid by the government. 3. All potential recipients of CSOP awards must be registered in the System for Award Management (SAM) before the recipient is awarded the CSOP contract. (https://www.sam.gov/SAM/) The General Solicitation describing the solicitation process and evaluation approach will be posted on or about Tuesday, April 14, 2020. All questions and comments regarding this special notice shall be submitted to email address COVID19CSOP@HQ.DHS.GOV.

Application Deadline: August 31, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

08/31/2020 - Research Grant for Pandemic Preparedness

The threat from newly emerging viral infections is one of the top global challenges for humanity. The recent COVID-19 pandemic shows that pandemic preparedness and having the right products and technology to fight infectious diseases with epidemic and pandemic potential is of utmost importance. It is required to act quickly to limit further substantial damages to society, economy and ecology. Project proposals will be considered that leverage modern technologies to create new breakthrough solutions to be more prepared for pandemic outbreaks or work towards existing solutions that could help to fight emerging viral infections.

Application Deadline: August 31, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

September 2020 Application Deadlines

09/01/2020 - Corporation for National and Community Service - RSVP Competition

The mission of CNCS is to improve lives, strengthen communities, and foster civic engagement through service and volunteering. Through AmeriCorps, Senior Corps, and the Volunteer Generation Fund, CNCS has helped to engage millions of citizens in meeting community and national challenges through service and volunteer action. Grants will help individuals and communities prepare for, respond to, recover from, and mitigate disasters and increase community resiliency. Activities may include assisting in disaster preparedness, response, recovery, and/or mitigation.

Application Deadline: September 1, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/07/2020 to 01/07/2021 - Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)

07-Sep-2020, 05-Oct-2020, 07-Jan-2021

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or straight clinical trials that lack translation as the primary motivation. This FOA will use the NIH Research Project (R01) award mechanism.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/08/2020 to 12/13/2021 - American Pharmacists Association Foundation - Incentive Grants for Residents and their Preceptors

The sponsor offers grants totaling more than $500,000, which has facilitated the development of over 500 pharmacy-based projects, improving the health outcomes of thousands of patients across the United States. These incentive grants offer pharmacists, students, and community pharmacy residents seed money to implement or support an existing innovative patient care service within their pharmacy practice. Incentive Grants are awarded annually on a calendar year. Grant recipients will be required to submit an interim report, a final project report, a final project expense report, and a short video summary of their project. Added in 2020, grants will also be offered with a focus on COVID-19 prevention, treatment, and testing.

Application Deadline: 08-Sep-2020 , 29-Mar-2021 , 07-Jun-2021 , 13-Dec-2021

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/08/2020 - Department of Energy - RFP -- Idaho National Laboratory COVID-19 Technical Assistance Program

The Department of Energy’s Office of Technology Transitions has announced new resources for innovators to combat COVID-19 through the COVID-19 Technical Assistance Program (CTAP). CTAP will provide targeted funding to DOE’s national laboratory system to assist non-DOE entities working to combat the coronavirus pandemic. CTAP is designed to allow external entities – including state, tribal and local governments; regional and local businesses; and other private sector entities – to engage directly with DOE lab researchers. These groups would be enabled to tap researchers’ technical expertise to work through and overcome difficult technical or scientific challenges related to combating the novel coronavirus. Funding provided under this program will cover up to 40 hours of consultation with INL staff. Work anticipated for CTAP projects is not R&D intensive, leverages INL’s unique capabilities or expertise and should not be intended to generate intellectual property. Only projects that provide COVID-19-related technical assistance to U.S. entities will be considered. Interested entities should provide: An technical representative at INL that will be the principle investigator that will work with you; Name and address of external entity requesting CTAP; The name of the representative that is your contact for your entity; Proposed project description, must include explanation of potential impact to work related to a COVID-19 response; Proposed funding request (funding request should be relatively small – e.g. 40 hours or $5,000) Funding decisions are made as proposals are received, based on available funding.  Entities that may be able to take advantage of this program should email td@inl.gov with the above information.  More information about INL’s expertise and capabilities can be found at www.inl.gov.  Additional beta.sam.gov information Notice Id       af63e86eb38841b4a89796455f0a4efc

Application Deadline: September 8, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/09/2020 - National Institute of Allergy and Infectious Diseases/NIH/DHHS - Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed)

Amount: $275,000

Application Deadline: September 9, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/24/2020 - Oak Ridge Institute for Science and Education - FDA Postgraduate COVID-19 Analysis Fellowship

A research opportunity is currently available with the Division of Plasma Protein Therapeutics (DPPT), in the Office of Tissues and Advanced Therapies (OTAT), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) located in Silver Spring, Maryland.

Application Deadline: September 24, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - Department of State - COVID-19 Small Grants Program

The Public Affairs Sections of the U.S. Mission to India, comprising the U.S. Embassy in New Delhi and the Consulates General in Hyderabad, Mumbai, Chennai, Kolkata, and North India, seeks to support effective coalitions that will bolster and leverage U.S.-India collaboration across a range of fields to fight COVID-19, in India and globally. The maximum award amount is $100,000.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - EPSRC UK-Robotics and Autonomous Systems (UK-RAS) Network - Medical Robotics for Contagious Diseases Challenge

30-Sep-2020 [LOI/Pre-App], 28-Oct-2020, 06-Nov-2020
The UK-RAS Network has announced a new Medical Robotics Challenge for Contagious Diseases.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - FDA-CBER-2020-0051 - FDA Influenza Immunity and Vaccination Postdoctoral Fellowship

A research opportunity is currently available in the Office of Vaccine Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - FDA-CBER-2020-0052 - FDA COVID-19 Diagnostic Test Fellowship

A research opportunity is currently available in the laboratory of Dr. Paul Carlson in the Office of Vaccine Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - Office of the Director, National Institutes of Health/NIH/DHHS - RFA-RM-20-020 -- NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional)

This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Transformative Research Award applications must be submitted in response to RFA-RM-20-013. The NIH Director’s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. The NIH Director’s Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Transformative Research Awards (through this FOA) or Early Independence Awards (through RFA-RM-20-021) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

09/30/2020 - Tasmanian Community Fund - COVID 19 Response Fund - Support, Connect and Rebuild - Medium Grants Program

The Tasmanian Community Fund is committed to making grants to community organizations that make a difference by improving the social, environmental, and economic wellbeing of the Tasmanian community.  The Tasmanian Community Fund is calling for medium applications that support Tasmanians and Tasmanian organizations to recover and rebuild from Covid19.  The TCF is seeking applications across three streams:

  • Support – supporting and meeting the needs of vulnerable people to ensure they are not left behind as a result of Covid19;
  • Connect – creating spaces and programs/processes to enable individuals and communities to reconnect and rebuild the social fabric of communities;
  • Rebuild – providing individual and organizational capacity building including options for realigning work and directions for the “new normal” and beyond.

Application Deadline: September 30, 2020

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

October 2020 Application Deadlines

10/01/2020 - Cystic Fibrosis Foundation - SARS-CoV-2 and Cystic Fibrosis Research Award

17-Jul-2020 [LOI/Pre-App], 01-Oct-2020
The Cystic Fibrosis Foundation is requesting Letters of Intent (LOIs) for basic science research projects that aim to improve our understanding of SARS-CoV-2 pathogenesis in cystic fibrosis. As the COVID-19 pandemic evolves, additional data will become available to shed light on populations that may have an increased susceptibility for contracting the disease as well as those who may experience a range in illness severity associated with this virus.

Letter of Intent Deadline: July 17, 2020

Application Deadline: October 1, 2020

More Information

10/05/2020 to 06/05/2022 - Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)

05-Oct-2020, 05-Feb-2021, 05-Jun-2021, 05-Oct-2021, 05-Feb-2022, 05-Jun-2022

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.

A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed.

This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

10/05/2020 - Genentech - Health Equity Innovations Fund

This call for grant proposals will support action-oriented research, demonstration projects, and programs to build the evidence base needed to promote health equity and reduce disparities in healthcare access, quality, and outcomes amongst populations facing the greatest needs – particularly communities of color. Funded proposals will develop, test, and/or scale strategies and interventions that reduce disparities and promote health equity. Successful proposals will also support health systems and hospitals, practitioners, advocates, community leaders, patients and caregivers, and decision-makers in setting priorities and allocating resources towards solutions that improve the health and wellbeing of historically underserved patients within Genentech’s disease areas of focus. Research projects must be U.S. based.

Letter of Intent Deadline: August 10, 2020

Application Deadline: October 5, 2020

More Information

10/06/2020 to 10/08/2021 - National Institute on Drug Abuse/NIH/DHHS - Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 7 priority areas in substance use epidemiology, prevention, and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service;6) partnerships between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies (e.g., the opioid crisis); 7) research collecting and examining data on the risks and outcomes associated with substance use and COVID-19 infection in the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).

Application Deadline: 06-Oct-2020 , 08-Feb-2021 , 08-Jun-2021 , 08-Oct-2021

More Information

10/13/2020 - RFA-HG-20-039 -- Laboratory, Data Analysis, and Coordinating Center (LDACC) for the Developmental Genotype-Tissue Expression Project (U24 Clinical Trial Not Allowed)

Funding Opportunity Announcement Number: RFA-HG-20-039

The National Human Genome Research Institute (NHGRI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development are coordinating efforts for establishing a Developmental Genotype-Tissue Expression (dGTEx) Project, to catalog and analyze transcriptional profiles from a wide variety of tissues obtained from neonates, children, and adolescents in a post-mortem setting. The purpose of this FOA is to solicit applications to develop and implement a Laboratory, Data Analysis, and Coordinating Center (LDACC) for the Developmental Genotype-Tissue Expression (dGTEx) Project. The LDACC will perform 2 major functions: a molecular laboratory, and a data analysis and coordinating center. As a molecular laboratory, the LDACC will work with the Biospecimen Procurement Center (BPC) funded by NICHD to process tissue samples for sequencing and biobanking. Responsibilities as a data analysis and coordinating center include ensuring close coordination with the BPC, monitoring study progress and laboratory performance, performing basic analysis of data for gene expression analyses, and harmonizing and submitting datasets to be deposited in repositories such as the AnVIL (Analysis, Visualization, and Informatics Lab-space).

Letter of Intent Deadline: October 13, 2020

Application Deadline: November 12, 2020

More Information

10/31/2020 - Ferring COVID-19 Investigational Grants

Ferring is interested in funding exploratory, basic, and clinical research grants to collect data and expand knowledge about the effects on SARS-CoV-2 on reproduction, pregnancy, and foetal/neonatal health. The programme will provide a limited number of research grants up to €25,000 for each application

Application Deadline: October 31, 2020

More Information

10/31/2020 - Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

The latest BARDA BAA is amendment 12 posted on February 10, 2020 which incorporates changes to AOI 7-Diagnostics. BARDA is now accepting submissions to AOI 7.7 for development of assays for coronaviruses. Due to an overwhelming response to Area of Interest 7, BARDA is temporarily closing AOI’s; Innovations (7.1), biothreats (7.2), antibiotic resistance (7.3) and influenza (7.6). AOI’s radiation exposure/biodosimetry (7.4), and chemical threat exposure (7.5) remain closed.

The final whte paper submission deadline is October 31, 2020.

The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

More Information

November 2020 Application Deadlines

11/04/2020 - RFA-DK-20-011 - Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)

Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. Severity, duration, and frequency of episodes of AKI as well as age, pre-existing CKD, and other comorbidities are associated with greater risks of CKD progression and death.

There is limited evidence to inform recommendations for processes of care or therapeutic interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. This is a missed opportunity to prevent chronic disease and premature death.

The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium composed of 3 to 4 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC) will develop and test interventions that aim to reduce morbidity compared with usual care in Stage 2 and 3 AKI survivors. This FOA pertains to the CCs.

Application Deadline: November 4, 2020

More Information

11/04/2020 - RFA-DK-20-012 - Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)

Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. Severity, duration, and frequency of episodes of AKI as well as age, pre-existing CKD, and other comorbidities are associated with greater risks of CKD progression and death.

There is limited evidence to inform recommendations for processes of care or therapeutic interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. This is a missed opportunity to prevent chronic disease and premature death.

The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium, composed of 3 to 4 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC), will develop and test interventions that aim to reduce morbidity compared with usual care in Stage 2 and 3 AKI survivors. This FOA pertains to the SDRC.

Application Deadline: November 4, 2020

More Information

11/10/2020 - RFA-DE-21-001 - Characterizing causal mechanisms to prevent dental fear and anxiety (R01 Basic Experimental Studies with Humans Required)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to test causal mechanisms underlying the etiology or prevention of dental fear, anxiety, or phobia. Novel insights about the causal forces that initiate, shape, or impede the development of dental fear will be essential for informing evidence-based interventions to prevent dental fear.

Application Deadline: November 10, 2020

More Information

11/18/2020 - Ecology and Evolution of Infectious Diseases (EEID)

The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.

Application Deadline: November 18, 2020

More Information

11/17/2020 - RFA-AA-20-009 - Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) solicits grant applications that propose research that can be translated into interventions in order to reduce infection and transmission of HIV in patients with alcohol use disorders.

Application Deadline: November 17, 2020

More Information

December 2020 Application Deadlines

12/16/2020 - RFA-DK-20-021 - Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.

Application Deadline: December 16, 2020

More Information

12/31/2020 - Travel and subsistence funding to support LMIC engagement during the COVID-19 outbreak

The awards will provide travel and subsistence funding to appropriately qualified public health professionals, clinicians and academics who wish to offer science and technical advice to support the immediate response to COVID-19 in low and middle-income countries. The awards are open to applicants who have a substantive position at a UK higher education institution or research organisation.

Application Deadline: December 31, 2020

More Information

April 2021 Application Deadlines

04/29/2021 - National Institute of Allergy and Infectious Diseases/NIH/DHHS - Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

Application Deadline: April 29, 2021

More Information

04/29/2021 - National Institute of Allergy and Infectious Diseases/NIH/DHHS - Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

Application Deadline: April 29, 2021

More Information

February 2023 Application Deadlines

02/03/2023 - BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement

Please see Special Instructions 001 Issuance for Easy Broad AgencyAnnouncement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of itsEZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV. See attachment(s).This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest(AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) inthe Office of Biomedical Advanced Research and Development Authority(BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal AcquisitionRegulation (FAR). Abstract submissions selected for award are consideredto be the result of full and open competition and in full compliance with41 U.S.C.

Application Deadline February 3, 2023

More Information

GCO Funding Opportunities

Monthly and continuous submission funding opportunity packets are available on the GCO Funding Opportunities web page.

STAY CONNECTED

Sign up for the Research Listserv to stay up to date with the latest news and events.